Parsons Capital Management Inc Crispr Therapeutics Ag Transaction History

Parsons Capital Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 09, 2021	SELL	$110.2 - $156.64 $187,891 - $267,071	-1,705 Closed	0 $0
Q4 2020 Feb 08, 2021	SELL	$79.67 - $173.23 $111,139 - $241,655	-1,395 Reduced 45.0%	1,705 $261,000
Q2 2020 Aug 10, 2020	BUY	$38.5 - $76.05 $119,350 - $235,755	3,100 New	3,100 $228,000
Q3 2018 Nov 13, 2018	SELL	$44.35 - $65.71 $183,165 - $271,382	-4,130 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$42.62 - $73.59 $176,020 - $303,926	4,130 New	4,130 $0

485

57.5M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.24B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Parsons Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Parsons Capital Management Inc with notifications on news.